ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Status:	Recruiting
Conditions:	Infectious Disease, Lymphoma, Lymphoma
Therapuetic Areas:	Immunology / Infectious Diseases, Oncology
Healthy:	No
Age Range:	Any
Updated:	2/13/2019
Start Date:	October 2016
End Date:	March 2022
Contact:	Eric Hong
Email:	ekjhong@stanford.edu
Phone:	650-736-6626

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome

The purpose of the study is to develop a prognostic index model for the rare disease of
mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical
data at various institutions. The investigators hope this will enable the identification of
low- and high-risk groups for survival in order to improve patient care and outcome.

Inclusion Criteria

- Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of
presentation to the participating center

- Patients that are expected to have care administered at the participating center or
jointly with referring physician(s) where follow-up data would be available

Exclusion Criteria

- Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to
advanced stage

- Patients diagnosed with advanced MF/SS more than 6 months prior to initial
presentation to the participating center

- Exclude one-time consultation type of new patients.

We found this trial at

sites

Stanford University School of Medicine

Palo Alto, California 94304

Principal Investigator: Youn Kim

Phone: 650-736-6626

from

Palo Alto, CA